Prognostic Factors of Non-epithelial Ovarian Cancer in a Tertiary Hospital in Indonesia
https://doi.org/10.47836/mjmhs.19.2.32
- Author:
Khoirunnisa Novitasari
1
;
Brahmana Askandar Tjokroprawiro
2
Author Information
1. Department of Obstetrics and Gynecology, Dr. Soetomo General Academic Hospital, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
2. Gynecology Oncology Division, Department of Obstetrics and Gynecology, Dr. Soetomo General Academic Hospital, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
- Publication Type:Journal Article
- Keywords:
Ovarian neoplasms, Prognostic factors, Disease free survival
- From:Malaysian Journal of Medicine and Health Sciences
2023;19(No.2):221-227
- CountryMalaysia
- Language:English
-
Abstract:
Introduction: Non-epithelial is a rare type of ovarian cancer but the most common ovarian neoplasm in reproductive
age. This study analyzed the correlation of clinical characteristics to disease-free survival (DFS) and 3-year survival
in non-epithelial ovarian cancer. Methods: A cohort analysis of medical records of 30 patients with non-epithelial
ovarian cancer from 2016 to 2017 at Dr. Soetomo General Academic Hospital. Survival analysis was performed using Kaplan–Meier test, log-rank test, and Cox regression to determine the correlation of characteristics including age,
stage, tumor size, tumor residue, histopathology type and chemotherapy status as prognostic factors for recurrence
and mortality. Results: DFS was significantly affected by stage (p=0.049), tumor residue (p<0.0001), and chemotherapy (p=0.005). Stage I, no residual disease, and adequate chemotherapy had the highest DFS and mean DFS
rates (94.1% and 35.6 months; 95.5% and 35.7 months; 75% and 31.94 months, respectively). Highest recurrence
rates were found in patients with unstaged disease (hazard ratio [HR]=10.08), residue >0 cm (HR=23.13), and inadequate chemotherapy (HR=6.55). Three-year survival was significantly affected by stage (p=0.001), tumor residue
(p<0.0001), and chemotherapy (p<0.0001). Stage I, no residual disease, and adequate chemotherapy had the highest 3-year survival rate and mean survival time (94.1% and 35.47 months; 95.5% and 35.7 months; 87.5% and 33
months). The highest mortality were found in patients with unstaged disease (HR=19.99), residue >0 cm (HR=11.33),
and inadequate chemotherapy (HR=11.71). Conclusion: Stage, tumor residue, and chemotherapy status in patients
with non-epithelial ovarian cancer are significant prognostic factors for DFS and 3-year survival.
- Full text:11.2023my1482.pdf
